Developing novel drugs for medulloblastoma
This research focuses on the development of novel drugs for the treatment of childhood brain tumours.
New drug combinations to treat neuroblastoma
This work focuses on defining how a new oncoprotein (called CARM1) we have discovered in neuroblastoma cells helps the cancer cells to survive, grow and avoid death.
Targeting nutrient use by childhood blood cancers
Looking at the molecular effects inside Acute Myeloid Leukaemia cells treated with a specific new drug and investigating if the drug can be combined with other standard treatments.
‘ALL’ about metabolism: repurposing drugs for acute lymphoblastic leukaemia
Examining whether a group of drugs called gliflozins could be used to treat T-ALL
Understanding the evolution of neuroblastoma to improve treatment
Single-cell transcriptomics linked to lineage tracing to interrogate the role of intra-tumour heterogeneity in shaping therapeutic susceptibility and resistance in paediatric cancer
Developing innovative new treatments for difficult to treat types of medulloblastoma
Developing and delivering small molecule drug and immunotherapy combinations for MYC-driven medulloblastoma: Efficacy, evolution and exploitation.
Improving treatment decisions and outcomes in low grade glioma
Development of a multi-factorial prognostic model to optimise treatment decision making and outcomes in paediatric low-grade glioma
Using next-generation gene technology to help children with blood cancers in low-income countries.
Defining the molecular landscape of paediatric and adolescent acute leukaemia in Tanzania
How does neuroblastoma begin and can we use this knowledge to develop new treatments?
Dissecting the role of MYCN in neuroblastoma initiation